Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported that Chief Operating Officer Eric Devroe had 604 shares of common stock sold on 2026-08-18 at $2.01 per share. According to the company, the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and Devroe now holds 146,349 shares directly.

Insider Trade Summary

Net Seller: 604 shares

Net Sell 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Sold 604 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	604	$2.01	$1K

Holdings After Transaction: Common Stock — 146,349 shares (Direct)

Footnotes (1)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Key Figures

Shares sold: 604 shares Sale price per share: $2.01 per share Shares owned after transaction: 146,349 shares

3 metrics

Shares sold 604 shares Common Stock transaction on 2026-08-18

Sale price per share $2.01 per share Common Stock sale on 2026-08-18

Shares owned after transaction 146,349 shares Directly owned by Eric Devroe following the sale

Key Terms

restricted stock units, mandatory tax withholding requirement, Form 4

3 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirement financial

"satisfy the mandatory tax withholding requirement upon vesting"

Form 4 regulatory

"reported in a Form 4 insider transaction filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did ACRV report for Eric Devroe?

Acrivon Therapeutics reported that COO Eric Devroe had 604 shares of common stock sold on 2026-08-18 at $2.01 per share, automatically to satisfy mandatory tax withholding upon vesting of restricted stock units.

How many ACRV shares did Eric Devroe sell and at what price?

Eric Devroe had 604 ACRV shares sold at a price of $2.01 per share. The filing describes the transaction as shares sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units.

Why were Eric Devroe’s ACRV shares sold in this Form 4 filing?

The filing states the shares were sold automatically to satisfy the mandatory tax withholding requirement that arose when Eric Devroe’s restricted stock units vested, rather than as a discretionary open-market sale.

How many ACRV shares does Eric Devroe own after this transaction?

After the reported transaction, Eric Devroe directly owns 146,349 shares of Acrivon Therapeutics common stock, according to the holdings reported following the sale in the Form 4.

Was the ACRV insider transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative. The footnote explains the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, rather than referencing a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:08 PM Accepted by SEC EDGAR 08/20/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		604	D	$2.01	146,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)